Insights

Recon takes an analytical look behind select developments in healthcare

Keep up with Recon Strategy Insights

Get an email each time we publish a new article

PDF: Trends in oncolytic virus therapeutics: then and now The idea of using pathogens to treat disease is not new; ranging from phage therapy to malariotherapy (resulting in the only Nobel in medicine…
PDF: Are some of Kaiser’s regional ambitions starting to pay off? We have produced a new study evaluating developments in Kaiser's regions (outside of California). The report provides an explanation f…
About the author: Alyssa Idusuyi is currently a high school senior attending Miss Porter's School (Connecticut). She spent the summer of 2022 with Recon Strategy as a paid intern assigned a project to…
Download a PDF of this article here. Ex vivo gene-therapies have been a game-changer for aggressive hematologic cancers. These products can effectively cure patients who otherwise had very low chance …
After the $9.7B acquisition of The Medicines Company two and a half years ago, Novartis is eager to demonstrate value with a successful launch of the primary target of the deal, Leqvio. This launch is…
Tirzepatide in pole position As previously described in this blog, GLP-1 agonists initially designed to treat glycemia in Type-2 diabetes are emerging as powerful weight loss agents in obesity indepen…
There isn’t a bricks-and-mortar primary care acquisition out there that is beyond Amazon’s financial reach.  While the announcement regarding One Medical has provoked fresh rounds of speculation about…
Download Here: Troubleshooting GT_Recon Strategy 2022 In the last decade, gene therapies have been a major area of development and interest. What kicked off with the approval of Spark Therapeutics’ Lu…
A cell therapy success against a solid tumor In CAR-T therapies, T-cells are transformed to express an antibody on their surface that allows them to home in on cancer cells and effect killing. This ap…
We use cookies
This website collects cookies to deliver better user experience and to analyze our website traffic and performance; we never collect any personal data or target you with ads.